Department of Biomedical Sciences, Asan Medical Institute of Convergence Science and Technology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Stem Cell Immunomodulation Research Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Nucleic Acids Res. 2021 Feb 26;49(4):2390-2399. doi: 10.1093/nar/gkab052.
CRISPR-based base editors (BEs) are widely used to induce nucleotide substitutions in living cells and organisms without causing the damaging DNA double-strand breaks and DNA donor templates. Cytosine BEs that induce C:G to T:A conversion and adenine BEs that induce A:T to G:C conversion have been developed. Various attempts have been made to increase the efficiency of both BEs; however, their activities need to be improved for further applications. Here, we describe a fluorescent reporter-based drug screening platform to identify novel chemicals with the goal of improving adenine base editing efficiency. The reporter system revealed that histone deacetylase inhibitors, particularly romidepsin, enhanced base editing efficiencies by up to 4.9-fold by increasing the expression levels of proteins and target accessibility. The results support the use of romidepsin as a viable option to improve base editing efficiency in biomedical research and therapeutic genome engineering.
基于 CRISPR 的碱基编辑器(BEs)被广泛用于在不引起破坏性的 DNA 双链断裂和 DNA 供体模板的情况下,在活细胞和生物体中诱导核苷酸取代。已经开发出诱导 C:G 到 T:A 转换的胞嘧啶 BEs 和诱导 A:T 到 G:C 转换的腺嘌呤 BEs。已经进行了各种尝试来提高这两种 BE 的效率;然而,为了进一步应用,它们的活性需要提高。在这里,我们描述了一个基于荧光报告基因的药物筛选平台,以鉴定具有提高腺嘌呤碱基编辑效率目标的新型化学物质。该报告系统表明,组蛋白去乙酰化酶抑制剂,特别是罗米地辛,通过增加蛋白质和靶标可及性的表达水平,将碱基编辑效率提高了高达 4.9 倍。这些结果支持将罗米地辛用作提高生物医学研究和治疗性基因组工程中碱基编辑效率的可行选择。